Target Name: NLRP6
NCBI ID: G171389
Review Report on NLRP6 Target / Biomarker Content of Review Report on NLRP6 Target / Biomarker
NLRP6
Other Name(s): Angiotensin II/vasopressin receptor | NALP6 | PAN3 | nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 6 | OTTHUMP00000230691 | NAVR/AVR | NLR family pyrin domain containing 6 | NACHT, leucine rich repeat and PYD containing 6 | PYPAF5 | NACHT, LRR and PYD domains-containing protein 6 | NACHT, LRR and PYD containing protein 6 | PYRIN-containing APAF1-like protein 5 | AVR | Nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 6 | NLRP6 variant 1 | angiotensin II/vasopressin receptor | NAVR | OTTHUMP00000147611 | NLR family pyrin domain containing 6, transcript variant 1 | NLRP6_HUMAN | CLR11.4 | NACHT, LRR and PYD domains-containing protein 6 (isoform 1)

NLRP6: A Drug Target / Disease Biomarker

The protein NLRP6 (Nuclear Factor of Activated T cells 6) is a key regulator of cellular stress responses and is involved in the immune and inflammatory responses. It has been implicated in a wide range of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. As a result, NLRP6 has become a focus of interest for researchers as a potential drug target or biomarker.

The NLRP6 protein is a cytoplasmic protein that plays a critical role in the regulation of cellular stress responses. It is a member of the nuclear factor of activated T cells (NFAT) family, which includes several other proteins involved in the regulation of cellular stress responses, including NFAT1, NFAT2, and NFAT3. NLRP6 is a 21-kDa protein that is expressed in a variety of tissues, including T cells, macrophages, and epithelial cells.

One of the key functions of NLRP6 is its role in the regulation of cellular stress responses. Stress can cause damage to cells, leading to the release of pro-inflammatory cytokines and the activation of stress-responsive signaling pathways. NLRP6 helps to regulate these processes by activating the DNA-binding domain of the protein, which allows it to interact with stress-responsive genes and regulate their expression.

In addition to its role in stress regulation, NLRP6 is also involved in the regulation of cellular signaling pathways that are important for both normal growth and development, as well as the regulation of inflammation. One of its most well-known functions is its role in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation, cell signaling, and inflammation-related diseases.

The NLRP6 protein has also been implicated in a wide range of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. For example, studies have suggested that NLRP6 may be involved in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, by contributing to the build-up of toxic protein aggregates in brain cells.

In addition, NLRP6 has also been implicated in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, by regulating the activity of T cells, which are a key part of the immune system. The NLRP6 protein has been shown to play a role in the regulation of T cell function by interacting with the protein PD-L1, which is a negative regulator of T cell function.

Furthermore, NLRP6 has also been implicated in the development of cancer by regulating the activity of signaling pathways that are important for cell growth, division, and survival. For example, studies have suggested that NLRP6 may be involved in the regulation of the PI3K/AKT signaling pathway, which is involved in the regulation of cell signaling pathways that are important for cancer growth and survival.

Given the wide range of functions of NLRP6, it is not surprising that it has become a focus of interest for researchers as a potential drug target or biomarker. Many studies have shown that NLRP6 is involved in the regulation of a wide range of cellular processes, including cell signaling pathways, DNA replication, and stress responses. As a result, NLRP6 has been identified as a potential drug target or biomarker for a wide range of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer.

In conclusion, the protein NLRP6 is a key regulator of cellular stress responses and is involved in the immune and inflammatory responses. Its role in the regulation of cellular stress responses, as well as its involvement in the regulation of signaling pathways that are important for both normal growth and development, and cancer make it a promising target for researchers as a potential drug

Protein Name: NLR Family Pyrin Domain Containing 6

Functions: Acts as the sensor component of the NLRP6 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to maturation and secretion of IL1B and IL18 (PubMed:30392956, PubMed:34678144). Inflammasomes are supramolecular complexes that assemble in the cytosol in response to pathogens and other damage-associated signals and play critical roles in innate immunity and inflammation (PubMed:30674671). Acts as a recognition receptor (PRR): recognizes and binds specific pathogens and other damage-associated signals, such as lipoteichoic acid (LTA), a cell-wall component of Gram-positive bacteria, or double stranded RNA (dsRNA) (PubMed:30392956, PubMed:34678144, PubMed:33377178). May also recognize and bind lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria; however, LPS is probably not a major activator of the NLRP6 inflammasome (PubMed:31932628, PubMed:34678144). Following LTA- or dsRNA-binding, NLRP6 undergoes liquid-liquid phase separation (LLPS), enhancing multivalent interactions, an essential step for the formation of the NLRP6 inflammasome polymeric complex (PubMed:34678144). The NLRP6 inflammasome acts by promoting recruitment of effector pro-inflammatory caspases (CASP1 and/or CASP4) that catalyze maturation and secretion of IL1B and IL18 in the extracellular milieu (PubMed:30674671, PubMed:12387869, PubMed:30392956, PubMed:34678144). The NLRP6 inflammasome plays a central role in the maintenance of epithelial integrity and host defense against microbial infections in the intestine (PubMed:30392956). Required to restrict infection against Gram-positive bacteria by recognizing lipoteichoic acid (LTA), leading to recruitment of CASP4 and CASP1, and subsequent maturation and secretion of IL1B and IL18 (PubMed:30392956, PubMed:33377178). Involved in intestinal antiviral innate immunity together with DHX15: recognizes and binds viral dsRNA to restrict infection by enteric viruses through the interferon pathway and GSDMD-dependent release of IL18 (PubMed:34678144, PubMed:34161762). Required to prevent infection by the apicomplexan parasite Cryptosporidium in enterocytes by promoting GSDMD-dependent release of IL18 (By similarity). The NLRP6 inflammasome may also regulate the gut microbiota composition by acting as a sensor of microbiota-associated metabolites to form a PYCARD/ASC-dependent inflammasome for downstream IL18 release and secretion of antimicrobial peptides (By similarity). Essential for gut mucosal self-renewal and proliferation (By similarity). Regulate mucus secretion in an inflammasome- and autophagy-dependent manner to prevent invasion by enteric bacteria, (By similarity). During systemic bacterial infections, the NLRP6 inflammasome negatively regulates neutrophil recruitment and neutrophil extracellular traps (NETs) formation (By similarity). May promote peripheral nerve recovery following injury via an inflammasome-independent mechanism (By similarity)

The "NLRP6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NLRP6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NLRP7 | NLRP8 | NLRP9 | NLRP9P1 | NLRX1 | NMB | NMBR | NMD3 | NMDA receptor | NME1 | NME1-NME2 | NME2 | NME2P1 | NME3 | NME4 | NME5 | NME6 | NME7 | NME8 | NME9 | NMI | NMNAT1 | NMNAT2 | NMNAT3 | NMRAL1 | NMRAL2P | NMRK1 | NMRK2 | NMS | NMT1 | NMT2 | NMTRQ-TTG10-1 | NMTRQ-TTG12-1 | NMTRV-TAC1-1 | NMU | NMUR1 | NMUR2 | NNAT | NNMT | NNT | NNT-AS1 | NOA1 | NOB1 | NOBOX | NOC2L | NOC2LP2 | NOC3L | NOC4L | NOCT | NOD1 | NOD2 | NODAL | NOG | NOL10 | NOL11 | NOL12 | NOL3 | NOL4 | NOL4L | NOL4L-DT | NOL6 | NOL7 | NOL8 | NOL9 | NOLC1 | NOM1 | NOMO1 | NOMO2 | NOMO3 | Non-protein coding RNA 185 | NONO | NOP10 | NOP14 | NOP14-AS1 | NOP16 | NOP2 | NOP53 | NOP56 | Nop56p-associated pre-rRNA complex | NOP58 | NOP9 | NOPCHAP1 | NORAD | NOS1 | NOS1AP | NOS2 | NOS2P1 | NOS2P2 | NOS2P3 | NOS3 | NOSIP | NOSTRIN | Notch ligands | Notch receptor | Notch Transcriptional Activation Complex | NOTCH1 | NOTCH2 | NOTCH2NLA | NOTCH2NLC | NOTCH3